Last reviewed · How we verify

CT-P13 — Competitive Intelligence Brief

CT-P13 (CT-P13) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α inhibitor (biosimilar). Area: Immunology / Rheumatology.

phase 3 TNF-α inhibitor (biosimilar) TNF-α (tumor necrosis factor-alpha) Immunology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

CT-P13 (CT-P13) — CMC Ambroise Paré. CT-P13 is a biosimilar of infliximab that binds to tumor necrosis factor-alpha (TNF-α) to reduce inflammatory signaling.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CT-P13 TARGET CT-P13 CMC Ambroise Paré phase 3 TNF-α inhibitor (biosimilar) TNF-α (tumor necrosis factor-alpha)
GP2015 Etanercept GP2015 Etanercept Sandoz phase 3 TNF-α inhibitor (biosimilar) TNF-α (tumor necrosis factor-alpha)
ABP 501 ABP 501 Amgen phase 3 TNF-α inhibitor (biosimilar) TNF-α
CT-L03 CT-L03 Celltrion phase 3 TNF-α inhibitor (biosimilar) TNF-α

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α inhibitor (biosimilar) class)

  1. Amgen · 1 drug in this class
  2. CMC Ambroise Paré · 1 drug in this class
  3. Celltrion · 1 drug in this class
  4. Sandoz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CT-P13 — Competitive Intelligence Brief. https://druglandscape.com/ci/ct-p13. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: